The FDA issued updates on November 29 regarding drugs that are currently in shortage:
- Amino Acids (New – Currently in Shortage)
- Diazepam Injection, USP (Updated – Currently in Shortage)
- Fentanyl Citrate (Sublimaze) Injection (Updated – Currently in Shortage)
- Hydromorphone Hydrochloride Injection, USP (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Discontinuation)
- Labetalol Hydrochloride Injection (Updated – Currently in Shortage)
- Lamotrigine Tablets (New – Discontinuation)
- Lovastatin Tablets (New – Discontinuation)
- Morphine Sulfate Injection, USP (Updated – Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated – Currently in Shortage)
- Tolmetin Sodium Tablets, USP (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
(Source: U.S. Food & Drug Adminstration)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!